Paxman and Dignitana Merge to Form a Unified and Stronger Company

The Merger of Paxman and Dignitana: A New Era in Scalp Cooling Treatments

In a significant move for the medical technology industry, Paxman and Dignitana have confirmed their merger, aiming to forge a more dynamic and unified entity. This strategic alliance is built on Paxman's established leadership in scalp cooling technology and seeks to leverage the strengths and capabilities of both companies. The merger primarily targets expanding their global reach, notably in the United States, where the number of facilities offering machine-assisted scalp cooling is expected to increase from 600 to 900.

This milestone comes after Paxman's recent public offer to acquire Dignitana, paving the way for a new collaborative phase in addressing the side effects experienced by cancer patients. The newly formed entity, Paxman AB, will not only enhance collaboration efforts but also share innovative insights and strengths, allowing the two companies to operate as a cohesive team focused on improving patient outcomes.

Paxman and Dignitana have spent years at the forefront of treating chemotherapy-induced side effects, with a shared mission and patient-centered vision. By working together, this unified company is dedicated to delivering consistent service levels through increased resources and expanded research and development (R&D) capabilities.

Currently, only 1% of cancer patients utilize scalp cooling devices from Paxman and Dignitana, indicating a vast opportunity for growth in the market. The merger creates significant synergies, allowing for increased investment in market expansion and R&D. By combining the strengths of both organizations, the merger promises not only commercial growth but also enhanced customer and patient benefits.

As Richard Paxman OBE, CEO of Paxman, stated, “This merger is a pivotal moment in our companies' histories, marking the start of a new chapter as we unite to form a stronger and more cohesive team. I look forward to collaborating and integrating the best of both organizations, harnessing our shared insights and strengths as we progress.”

The merger opens exciting growth opportunities, facilitating greater investments in market expansion and R&D for both companies. The integration of Paxman and Dignitana aims to deliver advantages not only in commerce but also for clients and patients alike.

Another crucial area of focus for the merged entity will be addressing the complex insurance reimbursement landscape in the United States. The undeniable synergistic value of this merger will empower Paxman to navigate and reshape the evolving reimbursement environment with greater agility and resilience, ensuring equitable patient access to these vital treatments.

Moreover, this merger establishes favorable conditions for introducing Paxman's innovative device explicitly designed to prevent chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. With commercialization planned for the second quarter of 2026, there exists a pressing and largely unmet clinical need for effective CIPN prevention, presenting a significant opportunity to enhance patient quality of life on a global scale. Preparing for the product's launch and implementation in the latter half of 2026, expanding the team in the U.S. will bolster operational capacity and strengthen their footing in this crucial market.

In conclusion, the merger of Paxman and Dignitana represents a powerful alliance in the medical technology sector, poised to drive innovation and improve patient care. By pooling resources and expertise, the two companies are set to become leaders in the scalp cooling treatment domain, making strides that could benefit cancer patients worldwide.